you, Thank study. us of made advancements you, Jordyn, last data human first readout areas afternoon. The our achievement was major positive thank the across quarter this joining everyone, for eventful. from CohBar of We significant for business, and the including our milestone a many quite
We also capital. human our strengthened
relevant Carol CohBar. wealth CohBar the part and members, Yun. Welcome Dr. board Nast a addition They and team. new the With and Joanne Carol each as of industry fortunate two are bring of them have of to Joanne to we expertise,
broader a also pathways. play genome regulation a peptide mitochondrial production, develop to the story believe what In and for excited better, of biological addition, in power to continue we novel variety think energy that terms although the of tend of the people our our us recently and advance fundamentals completed ahead. role have CohBar therapeutics, mitochondria to of primarily that operational harnessing allows been to the a much never extends We of is in leader our financing in runway lies pipeline. of a we're they
impacts has of We part and the or genome organs treatment enter power tissues. have process, encoded systemic physicians mitochondria the dramatically are the the important of this options to other provide circulation, potential of believe tapping cell they into the peptides secreted in many of tremendous improve for on outside mitochondrial and new valuable that our of the the and patients. of the approach lives As
which Our each NASH is more controlled the variety diseases, are of steatohepatitis our with potential phase need. top discuss with background, fibrotic has our as to as an fibrosis focused In pipeline development advanced treat CBXXXX. I'd data we nonalcoholic double well chronic Xa/Xb in conditions for medical on significant of the and line or of programs indication we initial under obesity, most treatment of like And unmet CBXXXX-X a programs believe randomized placebo that positive of from August, trial multi idiopathic detail. or to blind With these centered IPF. pulmonary CBXXXX, announced
Xb in during the it's takeaways While the results I our last worth portion detail study. the we of key review from quarterly reiterating the call, think
fewer this important a drug injection it of candidates of This off primary met with reactions. from is adverse profile target events also an non subject for analogs First, that program, validation occurring peptides naturally broader than hypothesis only tolerability in natural mitochondrial group, but CBXXXX the will endpoints developed effects than outcome of not and sources. derisking its our have than clean other safety study transient site occurring the tolerability, one more no in is
liver longer of and potential compared versus but four in when also key with to health. compared seen biomarkers Reductions weeks only terms inflammation subjects treated from of saw ALT assets placebo, NASH and which CDXXXX of placebo. compared reflective compares improvements phase development of markers in in time studies significant with are AST similar reduction ALT in points studies improved other for both products, to of liver we favorably these not to liver efficacy, damage The NASH. treatment currently In CBXXXX are XX% in decreased robust and in three
NASH encouraging that result CBXXXX with level reached resolution; the reduction the treated fact, four seen in weeks a potential ALT very In just CBXXXX. with had subjects of level reduction a of after of predictive treatment of of XX% is
XX Even of compared that only one preclinical our We with though result glucose of approved in a fact that the this demonstrated combined NASH believe have the placebo. as data particularly CBXXXX patients also is was in promising diabetes decrease XX% insulin the comorbidity. subjects light We significant a trial on the in diabetic. in signaling to group almost of
with treated weight subjects Additionally, towards CBXXXX a reduction. exhibited trend
liver were fat decreasing and the in the provided reversing We were in that diseases The additional inflammation presentation two Keep the fat than announced the selected data itself study. in fat the that for demonstrated NASH poster at fat liver between a arm results, the markers leaders and of poster subjects they the the substantial prior on the despite or damage CBXXXX ultimate eating NASH liver breaker we fact a in placebo fibrosis, the groups. one the lead only reductions active not were for the patients. the poster the we a and were context mind placebo we provided Notably, Rohit metabolism Loomba, group mentioned of which liver leading Finally, these in in of the key similar Dr. late the healthier liver field, the confined and enrolling liver reduction saw to last that content is the due and level earlier. believe inflammation improvements similar groups, of that to glucose is in both was trial, After duration in liver of in reductions to American diet the treating AASLD, related study. and I and author for of Study Association was slowing for objective in of held week. opinion and
In further issuance would program in generic prosecution barrier NASH. are for foundational the U.S. U.S., Book, the multiple patent of September currently of to methods counterparts therapeutic use, matter be foreign in to world. are Patent, countries There on to Orange term that which momentum additional new and throughout at stage as our FDA peptides, the IP as in entry. is new Finally, this a our the front in as the is covering patent the CBXXXX a XXXX. CBXXXX use of treat of patent least to due including of important this an gains The peptide of extends the eligible the well event related listing in the also approved patent the composition
to most such with setting experts phase reflect that CBXXXX other in an We've formulation of these that patients developments on key and the and a to work appropriate that NASH NASH. Taken advancement study we preparatory has a additional in have demonstrate design treatment significant great a program. leaders opinion before determine shows believe begin. with outpatient in together, duration impact could and study promise do longer Xa the for We the results meeting been clearly our disease meaningful study
NASH, opportunity to of with market Given million forward and the long of of it's with impact timelines represents associated program large our we to the treatment context dollars. and recent potential expense large billions in a and data size XX have with preferred U.S. in of very a the assets been the the be for CohBar path NASH partners. XXs in with would our discussing potential up partnership, estimated clinical developing people alone, the this for
agonists. use is developing clinical disease. synergistic cough, potential unknown generally a due a to-date, NASH in is and While disease that many age combination XX, which commonplace become demonstrated respiratory and including second no of to candidate, IPF. a anti fatigue. adults approved with progressive it's of expect classes is well-positioned models common of effects complexity preclinical IPF drugs, for due we our action more anti been We to drugs turn GLPX unique in include its in men. breath combination CBXXXX symptoms inflammatory persistent initially typically to regimens like are mechanism the and peptide broad that and the Initial is therapy cause believe now CBXXXX-X impacts properties to of have likely the shortness of with the to for over of fibrotic I'd other
is most years due survival and between them two to Unlike to side are cancers. While varies approved NASH, to currently worse three tolerate course of only disease effects. gastrointestinal the there drugs many is photosensitivity unable considerably after than which IPF patients the two are that individuals, mean treat diagnosis
patients mortality. loss continue remain morbidity experience and While outcomes current to significant treatment of and function, the delay poor, can lung of some
So there the annual the has efficacy drugs need on the improved therapeutics $X market, exceeding a of with billion is and safety for profile. an sales limitations Despite currently pressing better each believe per year. to currently peptide But our moment. program we Ken will face. say IPF this that that has the CBXXXX-X more in significant the patients needs unmet address about novel potential a
sheet balance clinical continue to enable both our public added a tremendous promise candidates, needed of to recently of which the million pipeline. completed offering, our we our to much advance us Given to capital $XX
clinical novel confidence recent even CBXXXX from power approach that us data drug Our of taking positive we development. gives the more in to are the
now first combined to previous progress and initiate excited funds in balance, additional are I hand human well-positioned Ken IPF now cash year. over program, an with the With review study we our about study our update continue will Ken? will pipeline on our to regarding plans are particularly our to current potential for to the including CBXXXX-X thinking next who design. our our
